Schall, Brown & Schwartz LLP is reminding Regeneron Pharmaceuticals shareholders about a class action lawsuit alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. The proposed class covers investors who purchased REGN shares from August 1, 2025, through May 15, 2026, with a Sept. 14, 2026, deadline to contact the firm about possible lead plaintiff appointments. The complaint alleges that Regeneron made false and misleading statements by suggesting its Phase III Fianlimab-Libtayo Study was likely to achieve its primary endpoint, while relying on flawed statistical assumptions and failing to demonstrate clinical differentiation from other therapies. The class has not yet been certified, and investors who take no action may remain absent class members. Appointment as lead plaintiff is not required to participate in any recovery.